Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort
Arthritis Care &Research, EarlyView.Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara +8 more
wiley +1 more source
EFFICACY OF FUROSEMIDE IN METHOTREXATE CLEARANCE IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE
Hematology, Transfusion and Cell Therapy, 2022 Objective: Methotrexate was first used in 1947 as a chemotherapeutic drug in the treatment of acute lymphoblastic leukemia (ALL). Methotrexate has been extensively explored as an anticancer drug since that time.
Saqib Khan +2 more
doaj
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. [PDF]
, 2016 IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical ...
DeMasi, Ryan +6 more
core +3 more sources
Arthritis Care &Research, EarlyView.As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox +3 more
wiley +1 more source
Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations [PDF]
arXiv, 2020 Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly.
arxiv
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus [PDF]
, 2016 Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects.
Attarbaschi, Andishe +20 more
core +2 more sources
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source
Frontiers in Pharmacology, 2020 High-dose methotrexate is a cornerstone agent in the chemotherapeutic treatment of patients with osteosarcoma. However, patients often develop methotrexate-induced toxicities.
Evelien G. E. Hurkmans +10 more
doaj +1 more source
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs [PDF]
, 1993 Heterotopic hamster hearts transplanted to unmodified LEW rats underwent humoral rejection in 3 days. Survival was prolonged to a median of 4 days with 2 mg/kg/day FK506.
Cramer, D +6 more
core +1 more source
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
New England Journal of Medicine, 2000 BACKGROUND Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis.
J. Bathon +11 more
semanticscholar +1 more source